Literature DB >> 11668121

Treatment of sepsis with activated protein C.

C J Hinds.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11668121      PMCID： PMC1121428          DOI： 10.1136/bmj.323.7318.881

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.

Authors:  B White; W Livingstone; C Murphy; A Hodgson; M Rafferty; O P Smith
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  Monoclonal antibodies in sepsis and septic shock.

Authors:  C J Hinds
Journal:  BMJ       Date:  1992-01-18

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

Authors:  F B Taylor; A Chang; C T Esmon; A D'Angelo; S Vigano-D'Angelo; K E Blick
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

6.  Time course of hemostatic abnormalities in sepsis and its relation to outcome.

Authors:  J A Lorente; L J García-Frade; L Landín; R de Pablo; C Torrado; E Renes; A García-Avello
Journal:  Chest       Date:  1993-05       Impact factor: 9.410

7.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

8.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study.

Authors:  M S Rangel-Frausto; D Pittet; M Costigan; T Hwang; C S Davis; R P Wenzel
Journal:  JAMA       Date:  1995-01-11       Impact factor: 56.272

9.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

10.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.

Authors:  C Brun-Buisson; F Doyon; J Carlet; P Dellamonica; F Gouin; A Lepoutre; J C Mercier; G Offenstadt; B Régnier
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272
View more
  2 in total

1.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors:  Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

Review 2.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Christian Gluud; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.